Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme

Two-year programme will research novel antimicrobial candidates from the Company's XF drug platform for use against dermal and ocularinfections

January 25, 2019
Destiny Pharma plc

Brighton, United Kingdom - 25 January 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the

development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has

been awarded funding of up to £1.6 million from a collaboration established under the UK-China AMR grant fund set up by Innovate UK and

the Department of Health and Social Care with the Chinese Ministry of Science and Technology. The two-year project will examine the use

of the Company's novel XF drugs to prevent, control, and eradicate life threatening bacteria or "superbugs" without generating resistance.

The research work will be carried out by Destiny Pharma's team in collaboration with expert groups at Cardiff University's School of

Dentistry and College of Biomedical and Life Sciences, led by Professor David Williams, and a team at Tianjin Medical University, China.

Full PR available here: